Cargando…
The effects of COVID-19 infection on the mortality of patients receiving rituximab therapy
BACKGROUND: Rituximab (RTX) is an important immunosuppressive agent used for many rheumatologic diseases. This study investigated the factors affecting mortality and mortality due to COVID-19 infection in patients receiving RTX. METHODS: From March 2020 to November 2021, 111 patients who were follow...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579651/ https://www.ncbi.nlm.nih.gov/pubmed/36258064 http://dx.doi.org/10.1007/s11845-022-03193-6 |